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Abstract
Binding of the urokinase-type plasminogen activator (uPA) to its cell-surface-bound receptor uPAR and
upregulation of the plasminogen activation system (PAS) correlates with increased metastasis and poor
prognosis in several tumour types. Disruptors of the uPA:uPAR interaction represent promising antitumour/metastasis agents and several approaches have been explored for this purpose, including the use
of small molecule antagonists. Two highly potent non-peptidic antagonists 1 and 2 (IC50 1 = 0.8 nM, IC50
2 = 33 nM) from the patent literature were reportedly identified using competition assays employing
radiolabelled uPAR-binding uPA fragments and appeared as useful pharmacological tools for studying the
PAS. Before proceeding to such studies, confirmation was sought that 1 and 2 retained their potencies in
physiologically relevant cell-based competition assays employing uPAR's native binding partner high
molecular weight uPA (HMW-uPA). This study describes a new solution phase synthesis of 1, a mixed
solid/solution phase synthesis of 2 and reports the activities of 1 and 2 in semi-quantitative competition
flow cytometry assays and quantitative cell-based uPA activity assays that employed HMW-uPA as the
competing ligand. The flow cytometry experiments revealed that high concentrations of 2 (10-100 μM)
are required to compete with HMW-uPA for uPAR binding and that 1 shows no antagonist effects at 100
μM. The cell-based enzyme activity assays similarly revealed that 1 and 2 are poor inhibitors of cell
surface-bound HMW-uPA activity (IC50 >100 μM for 1 and 2). The report highlights the dangers of
identifying false-positive lead uPAR antagonists from competition assays employing labelled competing
ligands other than the native HMW-uPA. © 2011 Elsevier Ltd. All rights reserved.
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Abstract
Binding of the urokinase-type plasminogen activator (uPA) to its cell-surface-bound receptor uPAR
and upregulation of the plasminogen activation system (PAS) correlates with increased metastasis and

poor prognosis in several tumour types. Disruptors of the uPA:uPAR interaction represent promising
anti-tumour/metastasis agents and several approaches have been explored for this purpose, including
the use of small molecule antagonists. Two highly potent non-peptidic antagonists 1 and 2 (IC50 1 = 0.8
nM, IC50 2 = 33 nM) from the patent literature were reportedly identified using competition assays
employing radiolabelled uPAR-binding uPA fragments and appeared as useful pharmacological tools
for studying the PAS. Before proceeding to such studies, confirmation was sought that 1 and 2 retained
their potencies in physiologically relevant cell-based competition assays employing uPAR’s native
binding partner high molecular weight uPA (HMW-uPA). This study describes a new solution phase
synthesis of 1, a mixed solid/solution phase synthesis of 2 and reports the activities of 1 and 2 in semiquantitative competition flow cytometry assays and quantitative cell-based uPA activity assays that
employed HMW-uPA as the competing ligand. The flow cytometry experiments revealed that high
concentrations of 2 (10−100 µM) are required to compete with HMW-uPA for uPAR binding and that
1 shows no antagonist effects at 100 µM. The cell-based enzyme activity assays similarly revealed that
1 and 2 are poor inhibitors of cell surface-bound HMW-uPA activity (IC50 > 100 µM for 1 and 2). The
report highlights the dangers of identifying false-positive lead uPAR antagonists from competition
assays employing labelled competing ligands other than the native HMW-uPA.

1. Introduction
The plasminogen activation system (PAS) plays a central role in a variety of tissue remodelling
processes including tumour invasion and metastasis.1,2 Metastasis has been clinically correlated with
upregulation of the PAS in multiple tumour types3-6 and at least two PAS components are considered
as promising targets for developing novel anti-cancer/metastasis therapeutics.7-9 In its simplest form,
the PAS comprises the serine protease urokinase-type plasminogen activator (uPA), its cognate GPIanchored cell surface-bound receptor (uPAR) and two endogenous serpins; plasminogen activator
inhibitor 1 (PAI-1) and plasminogen activator inhibitor 2 (PAI-2). Activation of uPA upon binding to
uPAR leads to cleavage of cell surface-associated plasminogen to reveal the broad spectrum serine
protease plasmin. Localisation of plasmin activity on cell surfaces at the leading edge of migrating
cells provides focussed activation of downstream extracellular zymogens (e.g. proelastases,
procollagenases and prostromelysins) and latent growth factors and together these lead to directional
pericellular proteolysis and remodelling of the local extracellular environment – key events required
during metastasis.10 A secondary function of the PAS is to activate further cell migration and
proliferation signalling via multimeric complexes involving uPAR, transmembrane integrins and
vitronectin.11-13

The two principle strategies that have been explored for dampening PAS activity with the goal of
producing new anti-cancer leads include: (1) inhibitors of the serine protease domain of uPA and (2)
antagonists of the uPA:uPAR interaction. Several structural classes of uPA inhibitors have been
identified and selected analogues have undergone preclinical evaluation as non-cytotoxic antitumour/metastasis drugs.14 An orally active uPA inhibitor (MESUPRON®) being developed by Wilex
AG (Germany) is currently undergoing phase II trials in patients with breast and pancreatic cancers
(http://www.wilex.de/R&D/Mesupron.htm).

The uPA-binding site presented by uPAR is a relatively large hydrophobic cavity (25 Å across, 14 Å
deep).15 Residues Asn22-Trp31 located on a β-hairpin loop of the amino-terminal fragment (ATF) of
uPA bury deeply into the cavity giving rise to a high affinity interaction (KD ~ 0.2 nM).16,17 Tyr24 is a
major contributor to high affinity as it is located at the tip of the β-hairpin and interacts with all three
uPAR domains (DI-DIII).17,18

Many of the known uPAR antagonists specifically target the hydrophobic cavity, with reported
examples including linear19 and cyclic20 peptides and fusion proteins bearing the uPAR binding
fragment of uPA.21 A limited number (five in total) of small molecule non-peptidic uPAR antagonists
have also been described.22 Other anti-uPAR strategies that have been explored include the use of
monoclonal antibodies23 and siRNA.24
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Of the few small molecule uPA:uPAR antagonists known two compounds show very high potencies:
Schering’s peptidomimetic derivative 1 (IC50 = 0.8 nM)25 and Chiron’s CHIR11509 2 (IC50 = 33 nM).26
Due to their high potencies, small size and synthetic accessibility compounds 1 and 2 appear to
represent useful pharmacological tools for probing the role of the PAS in metastasis.

The IC50 value for 1 was reportedly determined in a cell-based radioligand competition binding assay
using human prostate cancer DU-145 cells, which express high levels of unoccupied uPAR receptors,
and an 125I-labelled (125I−Tyr24) cyclic version of the minimal receptor-binding sequence of uPA
(residues 12−32, Ala19).25,27 The reported IC50 value for 2 was measured using a modified version of a
radioligand binding assay reported by Rosenberg and co-workers,28 where biotinylated soluble uPAR
is immobilised onto streptavidin-coated plates and the competitive binding of 125I-labelled uPA ATF
measured. The modified assay used in the IC50 determination for 2 substituted 125I-labelled uPA ATF
with a tagged version of the epidermal growth factor (EGF)-like domain of uPA.26, 29

While both 1 and 2 are clearly potent antagonists of labelled uPA fragments it was noted that neither
compound had to date been tested for their ability to compete with the native uPAR ligand (high
molecular weight uPA: HMW-uPA) for uPAR binding, or for their functional effects on plasminogen
activation in physiologically relevant cellular settings where the native ligand is present. Such
experiments are essential for uPAR antagonists being considered as anti-cancer/metastasis leads since
inhibition of uPA activation and downstream pericellular proteolysis is ultimately the effect required
for reducing tumour invasion and metastasis in vivo. This paper describes two new syntheses for 1 and
2 and reports the important finding that in physiologically relevant competition cell-based assays using
HMW-uPA both compounds are poor uPAR antagonists and show only minimal inhibition of uPA
activity at high (µM) concentrations.

2. Chemistry
Syntheses of 1 and 2 are described in the patent literature but few experimental details and no
compound characterisations were provided.25,26 The reported method for preparing 1 and various
analogues made use of Fmoc-based solid phase synthesis protocols on Sasrin resin. We now report the

synthesis and characterisation of 1 using a solution phase peptide synthesis strategy starting from the
commercially available 3’-aminobiphenyl-4-carboxylic acid 3 (Scheme 1).

Scheme 1. Synthesis of putative uPAR antagonist 1a

a

Reagents and conditions: (a) Boc2O, I2, DIPEA, 99%; (b) L-Phe-OMe.HCl, HBTU, DIPEA, 79-88%;

(c) (i) TFA, p-cresol, (ii) Boc-L-Trp-OH, HBTU, DIPEA, 53-65%; (d) (i) TFA, p-cresol, (ii) Ac2O,
DIPEA; (e) LiOH, THF/H2O, 90-95% (over 3 steps).

Intitial attempts to produce N-Boc-3’-aminobiphenyl-4-carboxylic acid 4 from 3 under standard
conditions using Boc-anhydride (Boc2O) proved surprisingly difficult (yields < 70%) but it was found
that very high yields (>99%) of 4 could be obtained when catalytic I2 was added to reactions.30 The
carboxylic acid 4 was coupled to L-Phe-OMe.HCl using O-benzotriazole-N,N,N’,N’-tetramethyluronium-hexafluoro-phosphate (HBTU) and diisopropylethylamine (DIPEA) in DMF to produce 5 in
79-88% yield. The N-Boc group was removed from 5 by stirring with neat trifluoroacetic acid (TFA) in
the presence of p-cresol as cation scavenger. The deprotected crude product was coupled to Boc-L-TrpOH using HBTU and DIPEA in DMF to afford 6 in 53-65% yield. Boc-deprotection of 6 (neat TFA/pcresol) followed by acetylation with acetic anhydride and hydrolysis of the methyl ester
(LiOH/THF/H2O) provided 1 in 90-95% yield over the final three steps.

The patented method for preparing the putative antagonist CHIR11509 226 made use of the solid phase
submonomer strategy reported by Zuckermann et al31 for producing oligo-N-substituted glycine
peptoids. The method involves coupling bromoacetic acid to Wang resin followed by halogen
substitution with N-(4,4’-dimethoxybenzhydryl)glycinamide. Further manipulations followed by resin
cleavage with 90% TFA/H2O apparently afforded compound 2. It is clear, however, that this procedure
would not yield 2 due to loss of the 4,4’-dimethoxybenzhydryl group during resin cleavage with TFA.
A new unambiguous mixed solid/solution phase synthesis of 2 based on the submonomer method is
now reported (Scheme 2).

Rink amide AM resin bearing an Fmoc-protected amine was deprotected using 20% piperidine in
CH2Cl2. Bromoacetic acid was coupled to the amino-functionalised resin using DCC and 4-(N,Ndimethylamino)pyridine (DMAP) in a mixture of N-methylpyrrolidone (NMP) and CH2Cl2.
Displacement of the bromide with H2N-Gly-OtBu.HCl in DMSO at 45 oC afforded a secondary amine
which was acylated with bromoacetic acid using the above method. Displacement of the newly
introduced bromide with β-naphthylamine in DMSO at 45 oC, followed by coupling of the secondary
amine to bromoacetic acid provided an α-bromocarbonyl which was subsequently displaced with
propargylamine (DMSO at 45 oC). The resin was then cleaved and the tert-butyl ester simultaneously
removed using a mixture of TFA:triisopropylsilane (TIPS):H2O to afford the free acid 7 (17%) after
purification by preparative rp-HPLC (Scheme 2). Solution phase amide coupling of 7 with 4,4’dimethoxybenzhydrylamine using HBTU and DIPEA in DMF gave the target peptoid 2 (28%) after rpHPLC. Interestingly, two-dimensional NMR experiments in DMSO-d6 revealed that 2 exists as a
slowly interconverting 1:1 mixture of cis/trans rotomers about the C(O)-N(β-naphthyl) tertiary amide,
a 1:0.87 mixture of cis/trans rotomers about the sterically hindered secondary amide bond and a 1:0.95
mixture of cis/trans rotomers about the remaining tertiary amide.

Scheme 2. Synthesis of putative uPAR antagonist 2a

a

Reagents and conditions: (a) 20% piperidine, CH2Cl2; (b) BrCH2CO2H, DCC, DMAP, NMP/CH2Cl2;

(c) H2N-Gly-OtBu.HCl, DIPEA, DMSO; (d) β-naphthylamine, DMSO, 45 oC; (e) propargylamine,
DMSO, 45 oC; (f) TFA:H2O:TIPS 95:2.5:2.5, rp-HPLC, 17%; (g) 4,4’-dimethoxybenzhydrylamine,
HBTU, DIPEA, rp-HPLC, 28%.

3. Results
Phorbol 12-myristate-13-acetate (PMA) is known to induce high expression levels of unoccupied cell
surface uPAR receptors in monocyte-like U-937 leukemia cells without a corresponding increase in
uPA expression.32 Accordingly, PMA-stimulated U-937 cells were used in a semi-quantitative
competition flow cytometry assay where the binding of HMW-uPA labelled with the fluorescent probe
Alexa-488 (Alexa-HMW-uPA) to cell surface uPAR receptors was measured in the presence/absence
of antagonists. PMA-stimulated U-937 cells were similarly used in a sensitive and quantitative cellbased fluorometric uPA activity assay wherein the rate of conversion of a fluorogenic uPA-selective
substrate by uPAR-bound HMW-uPA was measured in the presence/absence of uPAR antagonists.

Antagonists which compete with HMW-uPA for uPAR binding indirectly inhibit conversion of uPA
substrate thereby allowing for the determination of IC50’s of uPA inhibition by antagonists.

3.1. Characterisation of Alexa-HMW-uPA Binding to Cell Surface uPAR Receptors and
uPAR-bound HMW-uPA activity in U-937 cells.
Preliminary flow cytometry and uPA activity investigations were carried out to confirm that PMA
stimulated U-937 cells were suitable for use in the cell-based uPAR antagonist assays employing
HMW-uPA as the competing ligand. The flow cytometry experiments showed that binding of
exogenous Alexa-HMW-uPA to uPAR receptors on PMA-stimulated U-937 cells occurs in a dose
dependent manner (Figure 1A, closed circles) and that saturation of ~1 x 106 cells is achieved in the
presence of 40 nM Alexa-HMW-uPA or greater. Unstimulated U-937 cells showed no increases in
fluorescence upon addition of increasing concentrations of Alexa-HMW-uPA (Figure 1A, closed
circles) suggesting that the lower number of uPAR receptors present on these cells were pre-saturated by
endogenous uPA prior to the addition of Alexa-HMW-uPA. Accordingly, 1 x 106 PMA-stimulated U-937

cells and 40 nM Alexa-HMW-uPA were chosen for use when the competition flow cytometry assays
were carried out in the presence of antagonists (see Figure 2).

Preliminary fluorometric investigations of cell surface-bound HMW-uPA activity in PMA stimulated
U-937 cells were conducted using the fluorogenic uPA-selective substrate Z-Glu-Gly-Arg-AMC.HCl33
in the presence/absence of added exogenous HMW-uPA. Cell number-dependent fluorescence
increases were observed in both cases confirming cell-bound uPA activity. The low but measurable
uPA activity observed in the absence of exogenous HMW-uPA (Figure 1B, unshaded squares)
confirmed that PMA stimulated U-937 cells express low levels of endogenous receptor-bound uPA.
The rate of increase in fluorescence was found to be significantly higher (indicating higher cell-bound
uPA activity) in the presence of 40 nM exogenous HMW-uPA (Figure 1B, shaded squares). The assay

was subsequently extended to a competition format to determine the IC50 values of uPA inhibition by
antagonists (see Figure 3) and in all assays 40 nM exogenous HMW-uPA was added to enhance cell
surface-bound uPA activity and increase sensitivity.

Figure 1. (A) Characterisation of Alexa-HMW-uPA binding to uPAR receptors on U-937 cells by flow
cytometry. Unstimulated (unshaded circles) and PMA stimulated (shaded circles) U-937 cells were
incubated in the presence of increasing concentrations of Alexa-HMW-uPA and the geometric mean of
cell-associated fluorescence measured using dual colour flow cytometry. (B) Characterisation of
uPAR-bound HMW-uPA activity in U-937 cells. Increasing numbers of PMA stimulated U-937 cells
were pre-incubated in the absence (unshaded squares) or presence (shaded squares) of 40 nM HMWuPA and analysed for cell surface HMW-uPA activity using a fluorogenic uPA-selective substrate.

Initial rates of increase in fluorescence per min were measured. Values shown represent the mean ± SD
(n = 3) from representative experiments.

3.2. Evaluation of 1 and 2 as Antagonists of the HMW-uPA:uPAR Interaction in U-937 Cells
by Flow Cytometry.
Semi-quantitative competition flow cytometry experiments were used to assess compounds 1 and 2 as
antagonists of HMW-uPA. Two positive control antagonists were included for assay validation. These
were: (1) HMW-uPA which had been inactivated with Glu-Gly-Arg-chloromethyl ketone (i-uPA)34 and
(2) mouse anti-human uPAR monoclonal antibody (MAb #3936, American Diagnostica Inc. CT,
USA).35 Briefly, 1 x 105 PMA-stimulated U-937 cells were incubated with 1 and 2 or positive controls
before addition of Alexa-HMW-uPA (40 nM). After a further short incubation cell surface fluorescence
was measured by dual colour flow cytometry.

The i-uPA positive control strongly antagonised Alexa-HMW-uPA binding at concentrations of 10 nM
(80% reduction in binding) and 100 nM (90% reduction in binding). The anti-uPAR MAb produced a
70% reduction in binding when administered at 100 nM, which is in reasonable agreement with a
previous finding that 133 nM concentrations of the antibody produce 50% reductions in binding of
HMW-uPA to uPAR receptors on glioblastoma cells.35

Compound 1 produced no reduction of fluorescence relative to the negative control (no test compound)
indicating that it does not antagonise HMW-uPA binding, even at the high concentrations used (10 µM
and 100 µM) (Figure 3). The same concentrations of 2 reduced the observed fluorescence relative to
the negative control by approximately 60% (10 µM) and 50% (100 µM) (Figure 3). This indicated that

while 2 antagonises HMW-uPA binding its effects are relatively weak and require µM concentrations
to effectively compete with the native uPAR ligand.

Figure 2. Competition flow cytometry analysis of antagonists of the HMW-uPA:uPAR interaction in
U-937 cells. PMA stimulated U-937 cells were pre-incubated with 10 µM or 100 µM 1 or 2 prior to
incubating with 40 nM Alexa-HMW-uPA for 15 min. Binding of Alexa-HMW-uPA to cells was then
assessed using dual colour flow cytometry. The observed fluorescence is expressed as a percentage of
the fluorescence observed in the presence of 40 nM Alexa-HMW-uPA alone (i.e. no compound added).
Fluorescence decreases observed after pre-incubation with positive controls (1) HMW-uPA inactivated
with Glu-Gly-Arg-chloromethyl ketone (i-uPA; 10 nM and 100 nM) and (2) mouse anti-human uPAR
monoclonal antibody (MAb #3936; 100 nM) are shown for comparison. Values represent means + SD
(n = 3) from representative experiments.

3.3. Quantitative Analysis of 1 and 2 as Inhibitors of Cell Surface-Bound HMW-uPA Activity
in U-937 Cells.
Fluorescence enzyme activity assays using PMA-stimulated U-937 cells and the uPA-selective
fluorogenic HMW-uPA substrate were used to quantitate the effects of 1 and 2 on cell-surface-bound
HMW-uPA activity. i-uPA34 was included as a control. Briefly, 5 x 104 PMA-stimulated U-937 cells

were incubated with varying concentrations of 1, 2 or i-uPA for 30 min before adding HMW-uPA.
Cells were further incubated for 30 min before being washed twice by centrifugation with buffer,
transferred to a fluor plate containing fluorogenic substrate and fluorescence measurements recorded.
Changes in fluorescence per minute relative to controls (no test compound added) were plotted as a
function of the concentration of added compounds (Figure 3). The control compound i-uPA showed
potent inhibition of cell-bound HMW-uPA activity exhibiting an IC50 value of 2.9 nM. In contrast,
compounds 1 and 2 showed only very weak inhibitory effects with each showing IC50 values greater
than 100 µM.

.
Figure 3. Fluorescence assays of cell surface-bound HMW-uPA activity in PMA-stimulated U-937
cells. Cells were pre-incubated for 30 mins with a range of concentrations of (A) i-uPA, (B) 1 or (C) 2

before adding 40 nM HMW-uPA and incubating for a further 30 mins. Cells were washed, fluorogenic
uPA-specific substrate added and fluorescence measurements recorded. Initial rates of change in
fluorescence after subtraction of background fluorescence (cells only) are presented as a percentage of
control (no test compound added). Values represent means + SD (n = 3) obtained from representative
experiments.

4. Discussion and Conclusions
In addition to the hydrophobic cavity used to engage uPA there exists a second well characterised
protein-protein interaction site on uPAR which binds to the somatomedin B (SMB) domain of matrix
embedded vitronectin.36 The uPAR:vitronectin interaction is implicated in cell migration processes
such as, for example, cytoskeletal rearrangements37 and remodelling of focal adhesion sites.38
Importantly, occupancy of the hydrophobic binding site on uPAR by uPA leads to a 5-fold increase in
the affinity of uPAR for vitronectin (KD ~ 1.9 µM → KD ~ 0.4 µM),39,40 suggesting that pre-formation
of the uPA:uPAR complex may enhance uPAR:vitronectin adhesion in vivo. It would therefore be of
considerable interest to examine the effects of small molecule uPA:uPAR antagonists on the
uPAR:vitronectin interaction. Compounds 1 and 2 were reported in the patent literature as highly
potent uPAR receptor antagonists and seemingly represented excellent pharmacological tools for such
investigations.

It was noted that the potencies of 1 and 2 had only previously been measured using radioligand
binding assays employing labelled uPAR-binding uPA fragments as the competing ligands in place of
uPAR’s native ligand HMW-uPA.25,26 As a precautionary step before proceeding to further
pharmacological investigations with 1 and 2 we sought to confirm that both compounds retained their
high potencies in physiologically relevant cell-based competition assays with the native ligand HMWuPA. A semi-quantitative competition flow cytometry assay using uPAR-expressing U-937 cells and a

quantitative U-937 cell-based fluorescence assay were used for this purpose. Access to 1 and 2 was
afforded through two simple new syntheses.

Compound 1 was found to show no antagonist effects at 100 µM in the flow cytometry assay and only
weak inhibition of cell-surface uPA activity in the fluorescence assay (IC50 > 100 µM). Compound 2
was shown to be a weak uPAR antagonist at concentrations of 10 µM and 100µM and a weak inhibitor
of cell-surface uPA activity (IC50 > 100 µM). Nanomolar concentrations of positive controls (antiuPAR MAb and chloromethylketone-inactivated HMW-uPA) antagonised HMW-uPA binding and
inhibited cell surface uPA activity under the same assay conditions. These results are in direct contrast
to the high antagonist potencies reported for 1 and 2 from the competition assays using labelled uPA
fragments.25,26

One possible explanation for the conflicting results arises from the fact that the uPA fragments
employed in previous measurements contained 125I-labelled Tyr24 residues. As stated previously, Tyr24
is located at the tip of uPA’s β-hairpin loop and is crucial for high affinity uPAR binding. Evidence
shows that modification of Tyr24 with bulky groups (e.g. iodine) greatly reduces uPA’s affinity for
uPAR.41,42 Given this and the fact that data comparing the uPAR binding affinity of the 125I-Tyr24-uPA
fragments to their unlabelled counterparts appears not to have been reported suggests that the
previously reported IC50 values for 1 and 2 are not meaningful.

In conclusion, compounds 1 and 2 are poor antagonists of the uPA:uPAR interaction in
physiologically relevant cellular systems and are therefore not useful as small molecule probes for
investigations of the PAS. The report highlights the importance of using HMW-uPA as the competing

ligand in competition experiments aimed at identifying and/or measuring the potency of small
molecule uPAR antagonists as pharmacological tools or anti-cancer drug leads.

5. Experimental Section
5.1. General.
Rink amide AM resin (200-400 mesh) was purchased from Novabiochem. Peptide synthesis-grade
CH2Cl2 and DMF were purchased from Auspep. 4,4’-dimethoxybenzhydrylamine was purchased from
TCI Japan and 3’-aminobiphenyl-4-carboxylic acid from Parkway Scientific. Propargylamine and βnaphthylamine were purchased from Sigma Aldrich. RPMI 1640 powder and foetal calf serum (FCS)
used for cell culture experiments were purchased from Trace Bioscientific (NSW, Australia). Phorbol
12-myristate 13-acetate (PMA) and protease free bovine serum albumin (BSA) were purchased from
Sigma-Aldrich (USA). Mouse anti-human uPAR (# 3936) monoclonal antibody and Spectrozyme uPA
were obtained from American Diagnostica Inc (CT, USA). HMW-uPA fluorogenic substrate III (ZGlu-Gly-Arg-AMC.HCl; Z = benzyloxycarbonyl, AMC = amino-4-methylcoumarin) was purchased
from Calbiochem, (USA). Alexa-uPA conjugate was constructed using the Alexa Fluor ® 488 labelling
kit purchased from Molecular Probes Inc., USA. Incubation and wash buffers for all cell experiments
consisted of Dulbecco’s phosphate buffered saline (PBS, 1 mM CaCl2, MgCl2) and 0.1% BSA (pH
7.4). Previously described radio-ligand binding assays reporting nM potencies for 1 and 2 included
0.1% BSA in buffers.25-29 High Resolution Mass Spectra were obtained using a Waters QTOF Ultima
ESI Mass Spectrometer and were within ± 0.4% of the theoretical values. Compounds 1 and 2 were
purified to greater than 95% purity using a 19 x 150mm 5 µM SunfireTM PREP C18 OBDTM column on
a Waters LC150 Preparative HPLC System run at 20 mL/min with UV detection at 254 nm. 1 and 2
were analysed for purity using a 4.6 x 250mm 5 µM Phenomenex Luna C18 column on a Shimadzu
CLASS-LC10 VP HPLC system run at 1 mL/min with UV detection at 254 nm. Manual solid-phase

peptide synthesis was performed in a Peptides International water-jacketed reaction vessel using a St.
John Associates 180o variable rate shaker. 1H and 13C NMR spectra were recorded on a Varian
Premium Shielded 500 MHz NMR spectrometer at 25 oC. Chemical shifts are reported as δ (ppm)
relative to TMS (0 ppm). The abbreviations s (singlet), d (doublet), t (triplet), q (quadruplet), m
(multiplet) and bs (broad singlet) are used throughout.

5.2. 3’-[[(1,1-dimethylethoxy)carbonyl]amino][1,1’-biphenyl]-4-carboxylic acid (4)
3’-aminobiphenyl-4-carboxylic acid 3 (1.7 g, 6.8 mmol) was covered with dry MeOH (6.8 mL) and
stirred. A solution of I2 (170 mg, 0.68 mmol) and di-tert-butyl dicarbonate (1.48 g, 6.8 mmol) was
formed in a separate vessel using a minimal volume of dry MeOH and added to the stirred mixture.
DIPEA (1.186 mL, 6.8 mmol) was added dropwise to the stirred mixture, producing a solution that was
stirred for 5 h and then concentrated. The residue was diluted in EtOAc (80 mL) and washed with a 1
M HCl solution (40 mL) and saturated Na2S2O3 solution (3 x 40 mL). The washes were repeated, and
all aqueous layers were combined and extracted with EtOAc (3 x 30 mL). After separation the
combined organic layers were dried over MgSO4 and concentrated, yielding the N-Boc amino acid 4
(2.471 g, 99%) as an off-white solid: mp 210-212 oC (dec); 1H NMR (CD3OD) δ 8.09 (d, J = 8.5 Hz,
2H), 7.77 (t, J = 1.5 Hz, 1H), 7.71 (d, J = 8.5 Hz, 2H), 7.43 (dt, J = 1.5, 8.0 Hz, 1H), 7.37 (t, J = 8.0
Hz, 1H), 7.32 (dt, J = 1.5, 8.0 Hz, 1H), 1.54 (s, 9H); 13C NMR (CD3OD) δ 175.4, 155.4, 144.1, 142.6,
141.0, 137.9, 130.8, 130.2, 127.3, 122.4, 119.0, 118.4, 81.0, 28.7; HRMS (ESI) for C18H18NO4:
Expected 312.1236 [M – H]. Found 312.1242.
5.3. 3’-[[(1,1-dimethylethoxy)carbonyl]amino]-[1,1’-biphenyl]-4-carbonyl-L-phenylalanine
methyl ester (5).
N-Boc amino acid 4 (2.18 g, 6.96 mmol) was stirred in dry DMF (80 mL) along with HBTU (2.64 g,
6.96 mmol) and DIPEA (4.85 mL, 27.84 mmol). To the stirred solution was added L-phenylalanine

methyl ester hydrochloride (3.0 g, 13.91 mmol). After stirring under N2 for 24 h the solution was
concentrated before diluting with CH2Cl2 (50 mL). The organic layer was washed with saturated
NaHCO3 solution (2 x 40 mL) and brine (2 x 40 mL) and dried over MgSO4. The crude product was
purified by silica gel column chromatography using a 3:1 mixture of petroleum spirit (40-60 oC) and
EtOAc to yield 5 (2.914 g, 88%) as pale yellow crystals: mp 104-106 oC; 1H NMR (CDCl3) δ 7.75 (d, J
= 8.0 Hz, 2H), 7.69 (s, 1H), 7.58 (d, J = 8.0 Hz, 2H), 7.35 (d, J = 8.0 Hz, 1H), 7.33 (t, J = 8.0 Hz, 1H),
7.28 (d, J = 7.5 Hz, 2H), 7.24 (t, J = 7.5 Hz, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.15 (d, J = 7.5 Hz, 2H),
6.99 (s, 1H), 6.75 (d, J = 7.5 Hz, 1H), 5.11 (dd, J = 5.5, 14.0 Hz, 1H), 3.75 (s, 3H), 3.30 (dd, J = 5.5,
14.0 Hz, 1H), 3.22 (dd, J = 5.5, 14.0 Hz, 1H), 1.52 (s, 1H); 13C NMR (CDCl3) δ 172.0, 166.6, 152.8,
144.1, 140.4, 139.1, 135.8, 132.2, 129.2, 129.1, 128.4, 127.3, 127.0, 126.9, 121.4, 118.0, 117.1, 80.2,
53.5, 52.2, 37.6, 28.1; [α]D = -24.5o (c. 1.0, MeOH); HPLC (254 nm) tr 29.5 min; HRMS (ESI) for
C28H31N2O5: Expected 475.2233 [M + H]. Found 475.2240.
5.4. 3’-[N-[(1,1-dimethylethoxy)carbonyl]-L-tryptophylamino][1,1’-biphenyl]-4-carbonyl-Lphenylalanine methyl ester (6).
Compound 5 (200 mg, 0.42 mmol) and p-cresol (91 mg, 0.84 mmol) were stirred with neat TFA (2 mL)
under N2 for 1 h. The TFA was removed under a stream of N2 and the remaining residue was triturated
with diethyl ether (3 x 5 mL). The TFA salt was then dissolved in DMF (10 mL) and to the stirring
solution was added a solution of HBTU (175 mg, 0.46 mmol), Boc-L-Trp-OH (320 mg, 1.05 mmol)
and DIPEA (366 µL, 2.1 mmol) in a minimal volume of DMF. The solution was stirred for 24 h at rt
before concentration in vacuo. The residue was taken up into CH2Cl2 (15 mL) and washed with 0.1 M
HCl (2 x 10 mL), saturated NaHCO3 (2 x 10 mL) and brine (2 x 10 mL). The organic layer was
concentrated and the crude product purified by column chromatography using a 1:1 mixture of
petroleum spirit (40-60 oC) and EtOAc to yield 6 (181 mg, 65%) as a white solid: mp 168-170 oC; 1H
NMR (500 MHz, CDCl3) δ 8.59 (s, 1H), 8.13 (bs, 1H), 7.70 (d, J = 7.5 Hz, 1H), 7.66 (d, J = 8.0 Hz,

2H), 7.41 (d, J = 7.5 Hz, 2H), 7.38 (s, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.29 (m, 2H), 7.27 (m, 1H), 7.24
(t, J = 4.0 Hz, 1H), 7.21 (m, 1H), 7.19 (d, J = 8.0 Hz, 1H), 7.18 (d, J = 8.0 Hz, 2H), 7.17 (m, 1H), 7.09
(t, J = 7.5 Hz, 1H), 7.01 (s, 1H), 5.46 (s, 1H), 5.10 (dd, J = 6.0, 13.5 Hz, 1H), 4.70 (bs, 1H), 3.76 (s,
3H), 3.33 (bs, 1H), 3.30 (dd, J = 6.0, 13.5 Hz, 1H), 3.23 (bs,1H), 3.23 (dd, J = 6.0, 13.5 Hz, 1H), 1.44
(s, 9H); 13C NMR (125 MHz, CDCl3) δ 172.6, 170.5, 166.6, 155.9, 143.6, 140.4, 137.8, 136.3, 136.1,
132.2, 130.5, 129.2, 128.6, 127.4, 127.2, 127.1, 127.0, 123.4, 123.0, 122.3, 119.9, 119.8, 118.7, 118.7,
111.4, 110.3, 80.4, 55.7, 53.8, 52.5, 37.7, 28.7, 28.3; [α]D = -12.7o (c. 3.0, MeOH); HPLC (254 nm) tr
29.0 min; HRMS (ESI) for C39H41N4O6: Expected 661.3041 [M + H]. Found 661.3026.
5.5. 3’-(N-acetyl-L-tryptophyl-amino)(1,1’-biphenyl)-4-carbonyl-L-phenylalanine (1).
Compound 6 (88 mg, 0.13 mmol) and p-cresol (30 mg, 0.28 mmol) were stirred with neat TFA (2 mL)
under N2 for 1 h. The TFA was removed under a stream of N2 and the residue was triturated with
diethyl ether (3 x 5 mL). The TFA salt was then dissolved in DMF (5 mL) and to the stirring solution
was added acetic anhydride (26 µL, 0.28 mmol) and DIPEA (70 µL, 0.4 mmol). The reaction was
stirred at rt under N2 for 30 min before being quenched by the addition of saturated NaHCO3 solution
(40 mL). Stirring was continued for a further 30 min before the resulting suspension was extracted with
EtOAc (4 x 20 mL) and the combined organic layers washed with 0.1 M HCl (3 x 20 mL) before
drying over MgSO4. The solution was filtered and concentrated in vacuo to yield a light brown solid.
76 mg of the solid was suspended in H2O (1 mL) and stirred while THF was added dropwise until a
solution was obtained. LiOH.H2O (32 mg, 0.76 mmol) was then added and the solution stirred for 4 h
at rt. 2 M HCl (10 mL) was added and the acidic suspension extracted with EtOAc (3 x 10 mL). The
combined organic extracts were dried over MgSO4, filtered, concentrated in vacuo and the residue
taken up in DMSO (2 mL) and purified by preparative rp-HPLC using a gradient from 100% solvent A
(100% H2O, 0.1% TFA) to 10% solvent A:90% solvent B (90% CH3CN:10% H2O, 0.1% TFA) over 30
mins (tr = 14 mins). Pure fractions were combined and lyophilized to yield 1 (71 mg, 95%) as a light

brown solid: mp 186-188 oC; 1H NMR (500 MHz, (CD3)2SO) δ 10.83 (s, 1H, Biphenyl NH), 10.24 (s,
1H, Trp-NH), 8.77 (d, J= 7.5 Hz, 1H, Phe-NH), 8.25 (d, J = 7.5 Hz, 1H, Trp-NH), 7.93 (s, 1H, Ar-H
Ring A), 7.91 (d, J = 8.5 Hz, 2H, 2 x Ar-H Ring B), 7.68 (d, J = 8.5 Hz, 2H, 2 x Ar-H Ring B), 7.65
(m, 1H, ArH Trp), 7.64 (m, 1H, Ar-H Ring A), 7.41 (m, 2H, 2 x Ar-H Ring A), 7.33 (m, 3H, Ar-H Trp,
2 x Ar-H Phe), 7.28 (t, J = 7.0 Hz, 2H, 2 x Ar-H Phe), 7.19 (m, 2H, Ar-H Phe and Ar-H Trp), 7.05 (t, J
= 7.5 Hz, 1H, Ar-H Trp), 6.97 (t, J = 7.5 Hz, 1H, Ar-H Trp), 4.72 (dd, J = 14.0, 7.5 Hz, 1H, Phe-Hα),
4.65 (bs, 1H, Trp-Hα), 3.21 (dd, J = 8.5, 13.0 Hz, 1H, Phe-Hβ), 3.19 (dd, J = 5.5, 14.5 Hz, 1H, Trp-Hβ),
3.08 (dd, J = 11.0, 13.0 Hz, 1H, Phe-Hβ), 3.02 (dd, J = 8.5, 14.5 Hz, 1H, Trp-Hβ), 1.84 (s, 3H, AcCH3); 13C NMR (125 MHz, (CD3)2SO) δ 173.1, 170.9, 169.2, 165.9, 142.8, 139.6, 139.5, 138.2, 136.0,
132.8, 129.3, 129.0, 128.2, 128.0, 127.2, 126.4, 126.3, 123.6, 121.9, 120.8, 119.1, 118.5, 118.2, 117.8,
111.2, 109.9, 54.3, 54.2, 36.2, 27.9, 22.5; [α]D = -14.1o (c. 1.0, MeOH); HPLC (254 nm) tr 24.2 min,
100%; HRMS (ESI) for C35H33N4O5: Expected 589.2451 [M + H]. Found 589.2467.
5.6. 2-[N-[2-amino-2-oxoethyl]-2-[N-(naphthalen-2-yl)-2-(prop-2-ynylamino)acetamido]acetamido]acetic acid trifluoroacetate (7).
Rink amide AM resin (2 g, 0.63 mmol/g) was shaken in a 45 mL solid-phase peptide synthesis vessel
with 20% piperidine in CH2Cl2 (10 mL) for 20 min before draining and washing with CH2Cl2 (3 x 15
mL) and DMF (2 x 15 mL). The resin was reswollen with CH2Cl2 (15 mL). Bromoacetic acid (700 mg,
5 mmol) was combined with DCC (1.032 g, 5 mmol) in NMP (5 mL) and CH2Cl2 (10 mL). DMAP
(36.6 mg, 0.3 mmol) was added to the drained resin followed by the bromoacetic acid/DCC solution.
The mixture was shaken for 1 h at rt before draining and washing with CH2Cl2 (3 x 15 mL), DMF (2 x
15 mL) and isopropanol (2 x 15 mL). The resin was then dried in vacuo. The dry resin was reswollen in
DMSO (24 mL) and drained before a solution of H2N-Gly-OtBu.HCl (832 mg, 4.96 mmol) and DIPEA
(1.728 mL, 9.92 mmol) in DMSO (24 mL) was added. The mixture was shaken at 45 oC for 4 h before
draining and washing with DMF (6 x 36 mL) and CH2Cl2 (6 x 36 mL). The resin was reswollen in

CH2Cl2 (36 mL). Bromoacetic acid (700 mg, 5 mmol) was combined with DCC (1.032 g, 5 mmol) in
NMP (5 mL) and CH2Cl2 (10 mL). DMAP (36.6 mg, 0.3 mmol) was added to the drained resin
followed by the bromoacetic acid solution. The mixture was shaken for 1 h at rt before draining and
washing with CH2Cl2 (6 x 36 mL) and DMF (6 x 36 mL). The resin was reswollen with DMSO (24
mL) and drained before a solution of β-naphthylamine (716 mg, 5 mmol) in DMSO (30 mL) was
added. The mixture was shaken at 45 oC for 4 h before draining and washing with DMF (6 x 36 mL)
and CH2Cl2 (6 x 36 mL). The resin was reswollen with CH2Cl2 (36 mL). Bromoacetic acid (700 mg, 5
mmol) was combined with DCC (1.032 g, 5 mmol) in NMP (5 mL) and CH2Cl2 (10 mL). DMAP (36.6
mg, 0.3 mmol) was added to the drained resin followed by the bromoacetic acid solution. The mixture
was shaken for 1 h at rt before draining and washing with CH2Cl2 (6 x 36 mL) and DMF (6 x 36 mL).
The resin was reswollen with DMSO (24 mL) and drained before a solution of propargylamine (272
mg, 4.96 mmol) in DMSO (30 mL) was added. The mixture was shaken at 45 oC for 4 h before
draining and washing with DMF (6 x 36 mL) and CH2Cl2 (6 x 36 mL). The resin was then dried in
vacuo before treating with a mixture of 95% TFA:2.5% water:2.5% TIPS (36 mL) and cleaved for 1 h
at rt. After filtering into a collecting vessel the filtrate was concentrated in vacuo and the residue taken
up in DMSO (2 mL) and purified by preparative rp-HPLC using a gradient from 100% solvent A
(100% H2O, 0.1% TFA) to 10% solvent A:90% solvent B (90% CH3CN:10% H2O, 0.1% TFA) over 30
mins (tr = 9 mins). Pure fractions were combined and lyophilized to yield 7 (112 mg, 17 %) as a white
powder: mp >300 oC (dec); 1H NMR (500 MHz, (CD3)2SO) δ 9.60 (bs, 1H), 8.05 (s, 1H), 8.03 (m, 2H),
8.01 (m, 2H), 7.96 (m, 1H), 7.73 (s, 1H), 7.59 (t, J = 4.5 Hz, 1H), 7.55 and 7.53 (rotomer, d, J = 1.5
Hz, 1H), 7.34 (s, 1H), 7.235 (s, 1H), 4.64 and 4.63 (rotomer, s, 2H), 4.19 and 3.98 (rotomer, s, 2H),
4.05 and 3.89 (rotomer, s, 2H), 3.80 (s, 2H), 3.78 (s, 2H), 3.57 (s, 1H); 13C NMR (125 MHz,
(CD3)2SO) δ 170.8 and 170.8 (rotomer), 170.5 and 170.1 (rotomer), 168.0 and 167.8 (rotomer), 165.0,
137.7, 133.0, 132.5, 129.8, 128.1, 127.7, 127.2, 127.0, 126.9, 125.6, 79.5, 74.7, 50.7, 50.2 and 49.8

(rotomer), 49.4, 46.6, 35.4; HPLC (254 nm) tr 18.5 min, 100%; HRMS (ESI) for C21H23N4O5:
Expected 411.1668 M+. Found 411.1605.
5.7. N-[2-amino-2-oxoethyl]-N-[2-[bis(4-methoxyphenyl)methylamino]-2-oxoethyl]-2-[N[naphthalen-2-yl]-2-[prop-2-ynylamino]acetamido]acetamide hydrochloride (2).
Compound 7 (88 mg, 168 µmol), HBTU (82 mg, 216 µmol), DIPEA (137 µL, 786 µmol) and 4,4’dimethoxybenzhydrylamine, (94 mg, 386 µmol) were dissolved in DMF (1 mL) and stirred under N2
for 24 h. The solvent was removed in vacuo and the residue taken up into DMSO (2 mL) and purified
by preparative rp-HPLC using a gradient from 100% solvent A (100% H2O, 0.1% conc. HCl) to 10%
solvent A:90% solvent B (90% CH3CN:10% H2O, 0.1% conc. HCl) over 30 mins (tr = 15 mins). Pure
fractions were combined and lyophilized to yield 2 (32 mg, 28 %) as a light brown solid: mp >300 oC
(dec); 1H NMR (500 MHz, (CD3)2SO) δ 9.65 and 9.10 (rotomer, d, J = 8.0 Hz, 1H, NH); 8.16 (s, 1H,
NH2), 8.02 (m, 1H, Ar-Naphthyl), 8.01 (m, 1H, Ar-H Naphthyl), 7.98 (m, 2H, 2 x Ar-H Naphthyl),
7.91 (m, 1H, Ar-H Naphthyl), 7.70 (s, 1H, NH2+), 7.59 (m, 1H, Ar-H Naphthyl), 7.54 and 7.50
(rotomer, d, J = 8.5 Hz, Ar-H Naphthyl), 7.37 (s, 1H, NH2), 7.20 (s, 1H, NH2+), 7.13 and 7.11 (rotomer,
d, J = 8.5 Hz, 4H, 2 x Ar-H), 6.81 and 6.77 (rotomer, d, J = 8.5 Hz, 4H, 2 x Ar-H), 5.95 (m, 1H,
Benzhydryl-H), 4.60 and 4.59 (rotomer, s, 2H, Gly2-CH2), 4.21 and 4.03 (rotomer, s, 2H, Gly4-CH2),
4.11 and 3.90 (rotomer, s, 2H, Gly3-CH2), 3.80 (s, 2H, Propargyl-CH2), 3.77 (s, 2H, Gly1-CH2), 3.69
and 3.66 (rotomer, s, 6H, OCH3), 3.58 (s, 1H, Alkyne-H); 13C NMR (125 MHz, (CD3)2SO) 171.0 and
170.9 (rotomer), 168.1 and 168.0 (rotomer), 167.9 and 167.6 (rotomer), 165.0, 158.1, 137.7, 134.8 and
134.5 (rotomer), 133.0, 132.5, 129.8 and 129.8 (rotomer), 128.3 and 128.2 (rotomer), 128.2, 127.8,
127.2, 127.0, 126.9 and 126.8 (rotomer), 125.6 and 125.5 (rotomer), 113.7, 79.6, 74.7, 55.2 and 54.9
(rotomer), 55.1 and 55.1 (rotomer), 52.1 and 52.0 (rotomer), 51.9 and 51.5 (rotomer), 51.0 and 51.0
(rotomer), 46.6, 35.5; HPLC (254 nm) tr 24.7 min, 100%; HRMS (ESI) for C36H38N5O6: Expected
636.2822 M+. Found 636.2853.

5.8 Cell Culture.
Human monocyte-like U-937 cells were used for all assays (American Tissue Culture Centre, USA).
Cells were maintained in culture at 37 °C in a humidified incubator containing 5% CO2 (Thermo
Scientific) using pre-warmed RPMI 1640 media supplemented with 2 mM L-glutamine and 5% foetal
calf serum (FCS, heat inactivated). Cells were passaged every 3-4 days to maintain a population > 1 x
106 cells.mL-1.
5.9 PMA Treatment.
Cells were diluted in RPMI 1640 + 5% FCS to 2 x 105 cells.mL-1 and cultured for 7−8 h at 37˚ C.
Solutions of PMA in DMSO were added to the cells to provide final PMA concentrations of 100 nM
(final DMSO concentrations < 0.01%). Cells were then incubated for a further 16 h to induce optimal
uPAR expression.43
5.10 Preparation of i-uPA.
100 µL HMW-uPA (1 mg.mL-1, 19 µM in distilled water) was reacted with Glu-Gly-Arg-chloromethyl
ketone 100 µL (1 mM in distilled water) for 24 h at 4 °C to form i-uPA.34 Absence of activity was
confirmed by treating i-uPA (5 nM) with Spectrozyme uPA chromogenic substrate (0.125 mM in
distilled water) and monitoring (Spectramax Plus 384: Molecular Devices plate reader) for absence of
colour development at 405 nM.
5.11 Flow Cytometry Assays.
U-937 cells in log phase growth were re-suspended in cold PBS/BSA at 1 x 106 cells.mL-1 and preincubated with varying concentrations of antagonists. Compounds 1 and 2 were dissolved in DMSO
and diluted with PBS to varying concentrations such that final addition of diluted compounds to cells
yielded DMSO concentrations of 2% in each sample. Visible inspection of assay wells showed no
evidence of compound precipitation and cell viability was unaffected by this concentration of DMSO.

Control samples containing 2% DMSO without antagonists were included in all assays. Controls for
the i-uPA and MAb #3936 assays included an appropriate dilution of vehicle (PBS). All samples were
incubated on ice for 30 min before adding 40 nM Alexa-HMW-uPA. After 30 min incubations with
Alexa-HMW-uPA on ice, cells were washed twice in ice-cold PBS/BSA by centrifugation (300 x g, 5
min 4˚C) before final re-suspending in ice cold PBS containing 5 µg/ml propidium iodide. Viable (i.e.,
propidium iodide negative) cells in the samples were analysed by dual colour flow cytometry as
described in Ranson et al.44
5.12 Fluorometric HMW-uPA Activity Assays.
Cell surface-bound HMW-uPA activity was measured using the fluorogenic substrate Z-Gly-Gly-ArgAMC. Fluorescence observed in this assay is directly proportional to cell-bound HMW-uPA activity
due to the high specificity of the substrate for HMW-uPA.33 The excitation wavelength range of the
substrate is 365-380 nm and the emission wavelength range is 430-460 nm. PMA stimulated cells were
prepared as described above and incubated with test compounds for 30 min at 4 ˚C, after which HMWuPA (40 nM) was added and the cells incubated for a further 30 min at 4 oC. Cells were then washed
twice by centrifugation with PBS at room temperature, transferred to a fluor plate and overlayed with
an equivalent volume of buffer containing 1 mM Z-Gly-Gly-Arg-AMC to give a final concentration of
0.5 mM of the fluorogenic substrate. Fluorescence emission was measured immediately using an
Fluorostar Optima instrument at 37 ˚C (BMG Labtech, Offenburg, Germany). Data was recorded at 30
sec intervals over a period of 40-50 min. A sample to indicate background fluorescence containing
cells, fluorogenic substrate and buffer was included in assay plates. A control sample with no
antagonist added included both HMW-uPA and fluorogenic substrate to designate a fluorescence value
at full receptor occupancy in the presence of fluorogenic substrate. The background fluorescence was
subtracted from each reading before statistical analysis. Calculation of the rate of change in
fluorescence.min-1 allowed quantitative interpretation of fluorescence data and was generated using the
linear region of a graph where fluorescence was plotted against time.

5.13 IC50 Determinations.
The IC50 values (concentration (nM) required to inhibit 50% of uPA activity) were obtained by
conducting a log transformation of the inhibitor concentrations. Data was normalised to a common
scale, where 100% activity was equal to maximal uPA activity, indicated by the control samples
containing HMW-uPA and substrate, but no antagonist. Values were calculated from logarithmic
sigmoidal dose response curves using the variable slope parameter, generated from GraphPad Prism V.
5.01 software (GraphPad Software Inc.)
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